PIA
FENC icon

Piedmont Investment Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Piedmont Investment Advisors’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-197
Closed -$2K – 1457
2018
Q2 		$2K Buy
+197
New +$2.33K ﹤0.01% 2570

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piedmont Investment Advisors's FENC Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Fennec Pharmaceuticals (FENC) in Q3 2018, closing a stake of 197 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in FENC in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 48 funds tracked by Wall St. Rank hold FENC as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Fennec Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 197 Fennec Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Fennec Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Fennec Pharmaceuticals position peaked at $2K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.